BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 10, 2011
View Archived Issues
Bristol-Myers Squibb claims new tyrosine-protein kinase BTK inhibitors
Read More
New formylpeptide FPR2/ALX receptor agonists disclosed
Read More
Siena Biotech patents new inhibitors of hedgehog signaling
Read More
Vitae Pharmaceuticals describes novel 11-beta-HSD1 inhibitors
Read More
V-5 immunitor appears safe and effective in phase IIb tuberculosis trial
Read More
Study clarifies effect of amantadine on PD-associated dyskinesia
Read More
Clinical trial verifies mechanism of antisense oligonucleotide LY-2181308
Read More
New ligands claimed of nicotinic acetylcholine alpha7/alpha4beta2 receptors
Read More
FDA extends label for Actemra
Read More
First-in-human study evaluates multikinase inhibitor 4SC-203
Read More
Xoma reports interim phase II data on XOMA-052 in type 2 diabetes
Read More
Cyclacel provides overview of 2010 and outlines objectives for 2011
Read More
Amgen and Xencor to jointly develop XmAb-5871
Read More
DBV Technologies raises funds to support development of Viaskin Peanut
Read More
Pharmasset reports on two programs in HCV infection
Read More
Apaziquone enters Japanese phase I trial in bladder cancer
Read More
Teva Pharma adds women's health portfolio with acquisition of Theramex
Read More
Russian government clears Cel-Sci 's phase III Multikine trial in head and neck cancer
Read More
Spectrum Pharma and Viropro sign agreement for development of rituximab biosimilar
Read More
Opexa prepares pivotal phase III trial of Tovaxin in MS
Read More
Ziopharm Oncology and Intrexon partner to develop DNA-based oncology therapeutics
Read More
Inhibition of HSP 90 is efficacious in MET-amplified tumor cells
Read More
Ardea's phase IIb RDEA-594 trial in allopurinol-refractory gout meets endpoints
Read More
Zafgen reports topline phase Ib data on ZGN-433 in obesity
Read More
New PET tracer [76Br]-MBBG shows promise in imaging NET-positive tumors
Read More